American scientists have found in a new study that the oral drug daraxonrasib can nearly double the survival time of patients with advanced pancreatic cancer, a result being described as one of the most promising developments in the treatment of the disease.
The findings, published in the prestigious medical journal the New England Journal of Medicine, show that daily use of daraxonrasib in patients with advanced pancreatic cancer significantly increased survival compared to standard treatments.
According to the study, patients with advanced pancreatic cancer carrying RAS mutations who took daraxonrasib daily survived for an average of more than 13 months, while the average survival of patients receiving conventional treatments was reported at around 6.5 to 6.7 months.
The research involved 168 patients with pancreatic cancer who had previously undergone treatment. Researchers said daraxonrasib is an oral RAS inhibitor that can suppress the growth of cancerous tumours in some patients.
The study found that among patients who received the drug as a second-line treatment, a positive response was observed in around one-third of cases. The median progression-free survival also exceeded eight months.
Researchers said the drug’s side effects mainly included skin rash, diarrhoea, nausea, mouth inflammation, vomiting and fatigue. Severe side effects were reported in around 30 percent of patients, but researchers stressed that the therapeutic benefits of the drug were encouraging.
kk
Views: 1
